{"result": "(\"entity\"<|>TIROIDITIS DE RIEDEL<|>EVENT<|>Tiroiditis de Riedel is a rare form of thyroiditis characterized by fibrous tissue replacement of the thyroid gland, leading to hypothyroidism and potential complications such as hypoparathyroidism.)\n##\n(\"entity\"<|>MAYO CLINIC<|>ORGANIZATION<|>The Mayo Clinic is a renowned medical center known for its research and treatment of various medical conditions, including Riedel's thyroiditis.)\n##\n(\"entity\"<|>HASHIMOTO<|>EVENT<|>Hashimoto's thyroiditis is an autoimmune disorder that leads to chronic inflammation of the thyroid gland, differing from Riedel's thyroiditis which involves fibrosis.)\n##\n(\"entity\"<|>BARTHOLOMEW LG<|>PERSON<|>Bartholomew LG is an author of a study discussing the association of sclerosing cholangitis with Riedel's struma and fibrous retroperitonitis.)\n##\n(\"entity\"<|>FALHAMMAR H<|>PERSON<|>Falhammar H is a researcher who has published findings on the clinical presentation, treatment, and outcomes of Riedel's thyroiditis.)\n##\n(\"entity\"<|>EGSGAARD NIELSEN V<|>PERSON<|>Egsgaard Nielsen V is an author of a case report on a rare case of orbital involvement in Riedel's thyroiditis.)\n##\n(\"relationship\"<|>TIROIDITIS DE RIEDEL<|>HASHIMOTO<|>Tiroiditis de Riedel and Hashimoto's thyroiditis are both forms of thyroiditis but differ in their pathological characteristics, with Riedel's involving fibrosis and Hashimoto's being autoimmune<|>7)\n##\n(\"relationship\"<|>MAYO CLINIC<|>TIROIDITIS DE RIEDEL<|>The Mayo Clinic has conducted extensive research and treatment on Riedel's thyroiditis, contributing to the understanding of the condition<|>8)\n##\n(\"relationship\"<|>BARTHOLOMEW LG<|>TIROIDITIS DE RIEDEL<|>Bartholomew LG's research discusses the association of sclerosing cholangitis with Riedel's struma, indicating a clinical relevance<|>6)\n##\n(\"relationship\"<|>FALHAMMAR H<|>TIROIDITIS DE RIEDEL<|>Falhammar H's work focuses on the clinical presentation and treatment of Riedel's thyroiditis, highlighting its medical significance<|>8)\n##\n(\"relationship\"<|>EGSGAARD NIELSEN V<|>TIROIDITIS DE RIEDEL<|>Egsgaard Nielsen V's case report on orbital involvement in Riedel's thyroiditis adds to the clinical understanding of the disease<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: :76-82.\n- Beck-Peccoz P, Roncoroni R, Mariotti S, Medri G, Marcocci C, Brabant G, et al. G Sex hormone-binding globulin measurement in patients with inappropriate secretion of thyrotropin (IST): evidence against selective pituitary thyroid hormone resistance in nonneoplastic IST. J Clin Endocrinol Metab. 1990;71:19-25.\n- Lucas T, Páramo C, Torres E, Català M, Gilsanz A, Moreno B, et al. Guía clínica del diagnóstico y tratamiento del incidentaloma hipofisario. Endocrinol Nutr. 2006;53:9-12.\n- Safer JD, Colan SD, Fraser LM, Wondisford FE. A pituitary tumor in a patient with thyroid hormone resistance: a diagnostic dilemma. Thyroid. 2001;11:281-91.\n- Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol. 2003;148:433-42.\n\n## 3.3 Tiroiditis\n\n### 24. En la tiroiditis de Riedel, indique qué es verdad:\n\nA. La presencia de hipoparatiroidismo al inicio del cuadro clínico es muy frecuente.\nB. En la ecografía son características las adenopatías.\nC. El aumento del tiroides es discreto, la consistencia dura y generalmente el crecimiento es asimétrico.\nD. La fibrosis afecta únicamente al tiroides, a diferencia de la enfermedad esclerosante asociada a IgG4.\n\n#### COMENTARIO\n\nLa fibrosis de la tiroiditis de Riedel puede atrapar a las paratiroides y dar lugar a un hipoparatiroidismo. En algunas series recientes, como la de Falhammar et al., la presencia de hipoparatiroidismo alcanza a 7 de los 8 pacientes reportados. Sin embargo, revisiones más extensas, como la que recoge la experiencia de la clínica Mayo, cifra la incidencia de hipoparatiroidismo en un 14%, dato que también está recogido en otras revisiones (opción A falsa).\n\nLa tiroiditis de Riedel no se caracteriza por la asociación con adenopatías patológicas (opción B falsa).\n\nEn la tiroiditis de Riedel, el aumento de tamaño del tiroides no es exagerado, y tiene una consistencia dura. La fibrosis de la tiroiditis puede ser más o menos extensa, y puede afectar a un único lóbulo o llegar a afectar a todo el tiroides y estructuras adyacentes (opción C correcta).\n---\nTIROIDES 3\n\nPor último, la opción D es falsa. En efecto, se ha descrito asociación hasta en un 38% de los \ncasos con otros procesos fibróticos, como la fibrosis retroperitoneal, la fibrosis mediastíni-\nca, la colangitis esclerosante, la pancreatitis, la fibrosis lacrimal y la orbitaria.\n\nReferencias:\n• Bartholomew LG, Cain JC, Woolner LB, Utz DC, Ferris DO. Sclerosing cholangitis: its possible association with Riedel's struma and \n  fibrous retroperitonitis. Report of two cases. N Engl J Med. 1963;269:8-12.\n• de Lange WE, Freling NJ, Molenaar WM, Doorenbos H. Invasive fibrous thyroiditis (Riedel's struma): a manifestation of multifocal \n  fibrosclerosis? A case report with review of the literature. Q J Med. 1989;72:709-17.\n• Egsgaard Nielsen V, Hecht P, Krogdahl AS, Andersen PB, Hegedu L. A rare case of orbital involvement in Riedel's thyroiditis. \n  J Endocrinol Invest. 2003;26:1032-6.\n• Falhammar H, Juhlin C, Barner C, Catrina SB, Karefylakis C, Calissendorff J. Riedel's thyroiditis: clinical presentation, treatment and \n  outcomes. Endocrine. 2018;60:185-92.\n• Fatourechi MM, Hay ID, McIver B, Sebo TJ, Fatourechi V. Invasive fibrous thyroiditis (Riedel's thyroiditis): the Mayo Clinic Experience \n  1976–2008. Thyroid. 2011;21:765-72.\n• Hennessey JV. Riedel's thyroiditis: a clinical review. J Clin Endocrinol Metab. 2011;96:3031-41.\n\n## 25 Sobre la tiroiditis de Riedel, ¿cuál de los siguientes enunciados es cierto?\n\nA. En la tiroiditis de Riedel hay fibrosis tiroidea, mientras que no la hay en la tiroiditis de Hashimoto.\nB. La tiroiditis de Riedel puede revertir espontáneamente.\nC. En la tiroiditis de Riedel no hay elevación de los títulos de anticuer\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}